Case Report

Efficacy of perampanel in a patient with epilepsia partialis continua

H. Argente-Escrig * , A. Gómez-Ibáñez, V. Villanueva

Accepted 20 September 2017
Received in revised form 16 September 2017
Received 3 May 2017

ARTICLE INFO

Perampanel is the first-in-class selective and noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist. It is authorized in the U.S. and Europe as an add-on antiepileptic drug for partial-onset seizures, and for primary generalized tonic–clonic seizures. Single reports have also indicated a potential efficacy for myoclonic jerks. Here, we report a patient whose drug-resistant epilepsia partialis continua completely resolved after adding perampanel. She has remained seizure-free in an eighteen-month follow-up period. Epilepsia partialis continua reemerged transiently after perampanel was temporarily discontinued, with no recurrence after its reintroduction. Therefore, this effect was reproducible, and suggests that it might be worth trying perampanel in similar settings.

© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Perampanel (PER) is a third-generation antiepileptic drug (AED), first-in-class selective and noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist. It has been approved and marketed as an add-on AED in partial-onset seizures with or without secondary generalization [1], and in primary generalized tonic–clonic seizures in patients from 12 years of age [2]. Large series in real life have proven the efficacy of PER in focal epilepsy [3,4]. Furthermore, single reports and short series have suggested a potential efficacy of PER in other specific conditions, such as myoclonic jerks in progressive myoclonic epilepsy like Lafora disease [5–7], and in Lance–Adams syndrome [8]. Although its efficacy and safety in the elderly have been previously highlighted [3,9], no clinical experience has been reported among this special population in epilepsia partialis continua (EPC).

2. Case report

Our patient is a 76-year-old woman whose past medical history is significant for hypertension and dyslipidemia. In 2014, she was diagnosed with a left frontal meningioma after having motor partial-onset seizures and paresis in her right upper limb along with mild motor aphasia. After surgical removal, she was prescribed and administered levetiracetam (LEV) at 1000 mg/day, and became seizure-free for one year. In September 2015, she was admitted to the Neurology ward due to continuous involuntary movements of her right arm lasting seven days. On exam, she had continuous clonic movements on her right hand, forearm and hemiface, along with right upper extremity paresis and motor aphasia. The remaining neurological exam was normal. Multichannel digital electroencephalogram (EEG) recordings using the international 10–20 placement system were obtained throughout the episode. Background rhythm during the awakened stage showed an average voltage of 8 to 9 hertz alpha activity in the posterior regions that blocked with eye opening. Beta activity was observed in anterior regions. No epileptiform discharges or focal abnormalities were seen. There was no modification during photic stimulation and hyperventilation. A brain magnetic resonance imaging (MRI) showed no changes from an identical screening a year prior (Fig. 1.). Not withstanding uneventful EEG recordings, based on clinical grounds, the diagnosis of EPC was established. Initially, she was treated with 1.5 mg/day of clonazepam (CZP), 1000 mg/day of LEV, and 400 mg/day of lacosamide (LCM). Seizures faded away, but she became significantly drowsy. Therefore, we decreased CZP, which subdued drowsiness, but seizures relapsed. Afterwards, we introduced PER progressively, 2 mg/day for two weeks and then 4 mg/day, as maintenance treatment in polytherapy with LEV and LCM. We observed substantial improvement on 2 mg, and seizure-freedom was achieved on 4 mg, with no side effects.

Six months later, the patient reported significant irritability. Given the lack of seizures, PER was slowly tapered until discontinuation. Immediately, EPC showed up again, so PER was reintroduced slowly throughout four weeks until the previous dose of 4 mg/day was reached.
reached. EPC was suppressed again. She has remained seizure-free and no side effects were reported in the last appointment, twelve months later.

3. Discussion

EPC is a rare and especially refractory focal motor status epilepticus. It consists of regular jerking activity, typically involving the hand and face. It can be very persistent, lasting as long as years [10]. EPC may complicate common cerebral lesions such as brain tumors [11,12], or infrequent disorders like Rasmussen encephalitis [13,14], apart from many other conditions [15]. In our patient, we hypothesize that the meningioma remnants along with surrounding cerebral edema contributed to the development of an epileptogenic network in the left frontal area over several months, which eventually caused her to experience this type of seizure. EPC may produce detectable focal discharges of cortical origin [10]. However, a normal scalp EEG does not refute the diagnosis of EPC, as ictal EEG can be uneventful in 18% of patients [16]. In general, patients with EPC are rather drug-resistant, with 30% suffering persistent EPC despite polytherapy [16]. Recently, isolated cases of patients with EPC have shown a positive response to add-on LCM [17], vagal nerve stimulator [18,19] or neocortical electrical stimulation [20]. Based on previously communicated efficacy of PER in focal epilepsy and in other less frequent conditions (such as myoclonic jerks in different epileptic disorders [5–8]), we tried PER in this patient with refractory EPC. We used PER in combination with LEV and LCM, which resulted in a sustained suppression of seizures in an eighteen-month follow-up, with limited and temporary side effects. A challenge–dechallenge–rechallenge design was applied to test the efficacy of PER. EPC was suppressed when PER was added the first time (challenge), it relapsed after stopping this AED (dechallenge) and seizure-freedom was achieved again when PER was reintroduced (rechallenge). This evolution suggests that PER, possibly through a synergism with the other AEDs, is playing a key role in controlling the seizures in this patient. In addition, this case also illustrates that rational polytherapy, using a combination of AEDs with different mechanisms of action, is a recommended way to manage patients with refractory epilepsy. PER-related irritability can be avoided with a slow titration [3,21]. In our patient, it was controlled with a slowly progressive introduction (in the second attempt). Another titration schedule could have been considered given the impairment condition (e.g. starting with 4 mg instead of 2 mg). We decided to initiate PER with 2 mg because AED clearance and metabolism are reduced in the elderly, making them more susceptible to side effects. In addition, the effective dose (4 mg/day) was lower than the one used in randomized clinical trials (RCT) [22]. This fact may be due to her advanced age and supports the usefulness of real-world data to clarify unresolved issues in RCT, like titration and dosage.

4. Conclusion

We found that PER-polypharmacy proved to be effective in the long-term for a patient with refractory EPC. In the light of this observation, we recommend the use of PER as an add-on AED for refractory cases of EPC, and we suggest that slow titration and low doses be considered in the elderly to achieve an adequate tolerability.

Acknowledgments

The authors thank Ryan Ottney for editing the manuscript for non-intellectual content, and Esteve for funding the Open Access fee.

References

[1] Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III trials. Epilepsia 2013;54:1481–9.

[2] French JA, Krauss GL, Wechsler RT, Wang X-FF, DiVentura B, Brandt C, et al. Perampanel for tonic–clonic seizures in idiopathic generalized epilepsy: a randomized trial. Neurology 2015;85:950–7.

[3] Villanueva V, García M, López-González FJ, Rodrigo-Osorio X, Toledo M, Salar Puig J, et al. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study. Epilepsy Res 2016;126:201–10.

[4] Trinka E, Steinhoff BJ, Nikanorova M, Brodie MJ. Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol Scand 2016;133:60–72.

[5] Schölemmer K, Bauer S, Belke M, Hermens A, Klein K, Reif P, et al. Sustained seizure remission on perampanel in progressive myoclonic epilepsy (Lafora disease). Epilepsy Behav Case Rep 2013;1:118–21.

[6] Dirani M, Nasreddine W, Abdulla F, Beydoun A. Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep 2014;2:164–6.

[7] Goldsmith D, Minassian BA. Efficacy and tolerability of perampanel in ten patients with Lafora disease. Epilepsy Behav 2016;52:132–5.

[8] Steinhoff BJ, Bacher M, Kuth C, Staack AM, Korinne-Rei R. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep 2016;6:28–9.

[9] Rohracher A, Kalss G, Leitinger M, Granbichler C, Deak I, Dobesberger J, et al. Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data. Ther Adv Neurol Disord 2016;9:445–53.

[10] Cockrell OC, Rathwell J, Thompson PD, Marsden CD. Clinical and physiological features of epilepsy partialis continua. Brain 1996;119:393–407.

[11] Boter M, Brossard L. Epilepsia partialis continua with well-delimited subcortical frontal tumor. Epilepsia 1974;15:39–43.

[12] Bejri-Kamem H, Sala-Padró J, Toledo M, Santamaria E, Sarria S, Gonzalez-Cuevas M, et al. Epilepsia partialis continua: aetiology, semiology and prognosis in a Spanish adult cohort. Epileptic Disord 2016.

[13] Gray F, Sernari M, Baron H, Daumas-Dupont C, Luron P, Saunon B, et al. Chronic localised encephalitis (Rasmussen’s) in an adult with epilepsy partialis continua. J Neurol Neurosurg Psychiatry 1987;50:747–51.
[14] Aguilar MJ, Rasmussen T. Role of encephalitis in pathogenesis of epilepsy. Arch Neurol 1960;2:663–76.
[15] Triola E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia 2012;53(Suppl. 4): 127–38.
[16] Pandian JD, Thomas SV, Santoshkumar B, Radhakrishnan K, Sarma PS, Joseph S, et al. Epilepsia partialis continua—a clinical and electroencephalography study. Seizure 2002;11:437–41.
[17] Spalletti M, Comanducci A, Vagaggini A, Buiaardini L, Gippo A, Amantini A. Efficacy of lacosamide on seizures and myoclonus in a patient with epilepsy partialis continua. Epileptic Disord 2013;15:193–6.
[18] Shen Y, Xia F, Feng G, Liu L, Lin W, Liu Y, et al. Seizure freedom in epilepsy partialis continua (EPC) through vagus nerve stimulation (VNS) therapy: a case report. Epilepsy Behav Case Rep 2013;1:50–1.
[19] De Benedictis A, Freri E, Rizzi M, Franzini A, Ragona F, Specchio N, et al. Vagus nerve stimulation for drug-resistant Epilepsia Partialis Continua: report of four cases. Epilepsy Res 2013;107:163–71.
[20] Valentin A, Ughratdar I, Cheserem B, Morris R, Selway R, Alarcon G. Epilepsia partialis continua responsive to neocortical electrical stimulation. Epilepsia 2015; 56:e104–.
[21] Shah E, Reuber M, Goulding P, Flynn C, Delanty N, Kemp S. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study. Seizure 2016;34:1–5.
[22] Leppik IE, Wechsler RT, Williams B, Yang H, Zhou S, Laurenza A. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res 2015;110:216–20.